Carotid Stenosis Monitoring
For patients with carotid stenosis, perform non-invasive imaging (duplex ultrasound) at 1 month, 6 months, and annually after any revascularization procedure, and implement aggressive medical management with antiplatelet therapy, high-intensity statin therapy, and blood pressure control regardless of intervention status.
Surveillance Imaging Protocol
Post-Revascularization Surveillance:
- Obtain duplex ultrasound at 1 month, 6 months, and then annually after CEA or CAS to assess patency and detect new or contralateral lesions 1
- Once stability is established over an extended period, you may extend surveillance intervals
- Terminate surveillance when the patient is no longer a candidate for intervention 1
Key Imaging Considerations:
- Duplex ultrasound serves as the primary surveillance modality
- Use CTA or MRA as supplemental imaging when duplex findings are equivocal or when detailed anatomic information is needed for intervention planning 2
- For rapidly progressive restenosis threatening complete occlusion, confirm with duplex ultrasound plus another imaging method before considering reintervention 1, 3
Medical Management - The Foundation
All patients with carotid stenosis require aggressive medical therapy, which forms the cornerstone of stroke prevention:
Antiplatelet Therapy
- Post-CEA: Aspirin 81-325 mg daily, started before surgery and continued indefinitely 4
- Post-CAS: Dual antiplatelet therapy (aspirin 81-325 mg + clopidogrel 75 mg daily) for minimum 30 days, then transition to single agent 1, 3, 1
- Long-term (beyond first month): Choose aspirin 75-325 mg daily, clopidogrel 75 mg daily, or aspirin plus extended-release dipyridamole 4
Lipid Management
- High-intensity statin therapy is reasonable for all patients who have undergone CEA, irrespective of serum lipid levels 1
- This applies to both symptomatic and asymptomatic patients with carotid stenosis 2
Blood Pressure Control
- Administer antihypertensive medication as needed to control blood pressure before and after any revascularization 1, 3
- Aggressive BP management is a Class I recommendation 1
Additional Risk Factor Management
- Smoking cessation with pharmacologic support (varenicline or nicotine replacement) as needed
- Mediterranean-style diet and regular physical activity
- Diabetes management with preference for SGLT2 inhibitors and GLP-1 receptor agonists due to cardiovascular benefits 5
Reintervention Thresholds
When to Consider Repeat Revascularization:
Symptomatic Recurrent Stenosis:
- For patients with symptomatic cerebral ischemia and recurrent stenosis (intimal hyperplasia or atherosclerosis), repeat CEA or CAS is reasonable using the same criteria as initial revascularization 1, 3
Rapidly Progressive Stenosis:
- Reoperative CEA or CAS is reasonable when duplex ultrasound plus confirmatory imaging identify rapidly progressive restenosis threatening complete occlusion 1, 3
Asymptomatic Recurrent Stenosis:
- May consider reoperative CEA or CAS in asymptomatic patients with recurrent stenosis using initial revascularization criteria (Class IIb recommendation) 1, 3
- Do NOT perform reintervention in asymptomatic patients with <70% stenosis that has remained stable over time (Class III: Harm) 1, 3
Critical Pitfalls to Avoid
- Never abandon medical therapy: Even after successful revascularization, medical management remains essential and should never be discontinued
- Don't over-surveil stable disease: Once extended stability is established, you can reasonably extend surveillance intervals rather than continuing frequent imaging indefinitely
- Avoid intervention on stable asymptomatic stenosis <70%: This carries more harm than benefit 1, 3
- Don't forget contralateral surveillance: Annual imaging should assess for development of contralateral lesions, not just the treated side 1
Special Populations
Patients with Contralateral Carotid Occlusion:
- These patients warrant closer surveillance as they may have higher stroke risk than typical asymptomatic stenosis patients
- Consider more aggressive monitoring intervals, though specific guidelines don't provide distinct protocols for this subset
Asymptomatic vs. Symptomatic Disease:
- The surveillance schedule remains the same regardless of initial symptom status
- Medical management intensity should be equally aggressive in both groups 2
The 2018 Canadian guidelines 2 and 2011 ASA/ACCF/AHA guidelines 1, 3 are concordant on these surveillance and medical management recommendations, providing strong consensus despite being from different societies and time periods.